INTERQUIM INTERQUIM

X
[{"orgOrder":0,"company":"NanoSurface Biomedical","sponsor":"NIH","pharmaFlowCategory":"D","amount":"$4.6 million","upfrontCash":"Undisclosed","newsHeadline":"NanoSurface Biomedical Awarded $1.9M in Funding from NIH","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"March 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"NanoSurface Biomedical"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Product Type
          filter News Type

            Active Filter(s):

            Product Type

            Companies

            Details:

            The SBIR funding will be used to develop NanoSurface’s innovative platform for modeling and assessing human cardiac function on-a-chip.

            Lead Product(s): Human iPSC-derived cardiac tissues

            Therapeutic Area: Pharmacology/Toxicology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: NIH

            Deal Size: $4.6 million Upfront Cash: Undisclosed

            Deal Type: Funding March 03, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY